Featured news from NHIVNA
HIV-related news from NAM
Benefits of early HIV treatment are clear, but issues raised by START and D:A:D remain unresolved
Liz Highleyman, 2015-10-23 00:10:00
The long-running controversy over when to start antiretroviral therapy (ART) has been definitively answered, but research is still needed to fully understand the implications of the large START and D:A:D studies, Professor Jens Lundgren of the University of Copenhagen said yesterday at a joint plenary session of the 15th European AIDS Conference and the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. Unresolved issues include the long-term effects of decades of antiretroviral drug exposure and the mechanisms underlying co-morbidities such as cardiovascular disease and cancer in people living with HIV.
Prof. Lundgren was a principle investigator for the START (Strategic Timing of Antiretroviral Treatment) and D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) studies, which have provided some of the key evidence informing the evolution of clinical practice. At the conference opening ceremony he was given the European AIDS Clinical Society (EACS) Award for Excellence in HIV Medicine in recognition of his contributions.
Source:1
